Products BIW-8962
BIW-8962 Phase 1 Terminated 💤 Quiet Interest: 21/100
Oct 1, 2008 → Oct 1, 2011
About BIW-8962 BIW-8962 is a phase 1 stage product being developed by Kyowa Kirin for Multiple Myeloma. The current trial status is terminated. This product is registered under clinical trial identifier NCT00775502. Target conditions include Multiple Myeloma.
What happened to similar drugs? 20 of 20 similar drugs in Multiple Myeloma were approved
Clinical Trials (2) NCT ID Phase Status Start Completion Indication NCT01898156 Phase 1/2 Terminated Jul 1, 2013 Jun 1, 2016 Phase 1 Portion : Non Small Cell Lung Cancer(NSCLC), Small Cell Lung Cancer(SCLC), Mesothelioma NCT00775502 Phase 1 Terminated Oct 1, 2008 Oct 1, 2011 Multiple Myeloma
Product Company Stage Hype Score mRNA-1195 Moderna Phase 2 NEX-20A Nanexa AB Phase 1 mRNA-2736 Moderna Phase 1 mRNA-2808 Moderna Phase 2 Placebo + Pirtobrutinib Eli Lilly Phase 2 Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomide Eli Lilly Phase 1/2 agenT-797 MiNK Therapeutics Phase 1 Duloxetine Hydrochloride (HCI) + Placebo Eli Lilly Phase 3 Temferon Genenta Science Phase 1/2 CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab) Celltrion Phase 3 CT-P53 + US-Ocrevus + EU-Ocrevus Celltrion Phase 3 CS-0777 tablets + CS-0777 tablets + CS-0777 tablets Daiichi Sankyo Phase 1 ASP7487, Velcade, Dexamethasone Astellas Pharma Phase 1/2 PHE885 Novartis Phase 2 Mirabegron + Placebo Astellas Pharma Approved Solifenacin Succinate + Solifenacin Succinate + Oxybutynin Hydrochloride + Placebo Astellas Pharma Approved Denileukin Diftitox (Ontak) Eisai Phase 1 Palonosetron Eisai Phase 2 KRN125(pegfilgrastim), PLR001(plerixafor) + KRN8601(filgrastim), PLR001(plerixafor) Kyowa Kirin Phase 2 KW-2478 + Bortezomib Kyowa Kirin Phase 1/2